Annual Meeting-SITC 2017: Immunotherapy Trends for 2017

Annual Meeting-SITC 2017: Immunotherapy Trends for 2017

AnnualMeeting-SITC2017

2 years
1,050 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
James L. Gulley, MD, PhD of National Cancer Institute at the National Institutes of Health gives an overview of the new and upcoming trends of 2017 for immunotherapy. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.
Up Next Autoplay
Viral Therapy Results Triggers Race to Complete Clinical Trials
Viral Therapy Results Triggers Race to Complete Clinical Trials
Category: Acute Lymphoblastic Leukemia
1,002 Views
AnnualMeeting-SITC2017 2 years
Viral Therapy May Prove to Be a Transformational Addition to Immuno-Oncology
Viral Therapy May Prove to Be a Transformational Addition to Immuno-Oncology
Category: Acute Lymphoblastic Leukemia
1,406 Views
AnnualMeeting-SITC2017 2 years
Recombinant Measles and Vesicular Stomatitis Virus are Ideal Adjunct to Checkpoint Immunotherapy
Recombinant Measles and Vesicular Stomatitis Virus are Ideal Adjunct to Checkpoint Immunotherapy
Category: Acute Lymphoblastic Leukemia
347 Views
AnnualMeeting-SITC2017 2 years
Stress Reducing Beta Blockers Combined With Immunotherapy May Increase Response Rates in Cancer Patients
Stress Reducing Beta Blockers Combined With Immunotherapy May Increase Response Rates in Cancer Patients
Category: Acute Lymphoblastic Leukemia
504 Views
AnnualMeeting-SITC2017 2 years
Retrospective Analysis Suggests Patients on Beta Blockers May Do Better on Immunotherapy Treatments
Retrospective Analysis Suggests Patients on Beta Blockers May Do Better on Immunotherapy Treatments
Category: Acute Lymphoblastic Leukemia
331 Views
AnnualMeeting-SITC2017 2 years
Higher Stress Levels in Mice Cause a Reduced Response Rate in Immunotherapy
Higher Stress Levels in Mice Cause a Reduced Response Rate in Immunotherapy
Category: Acute Lymphoblastic Leukemia
559 Views
AnnualMeeting-SITC2017 2 years
New Data Suggests Immunosenescence May Not Be a Factor in Immunotherapy Treatment
New Data Suggests Immunosenescence May Not Be a Factor in Immunotherapy Treatment
Category: Acute Lymphoblastic Leukemia
692 Views
AnnualMeeting-SITC2017 2 years
Pembrolizumab + Radiation Combination Shows Promise in Triple Negative Breast Cancer
Pembrolizumab + Radiation Combination Shows Promise in Triple Negative Breast Cancer
Category: Acute Lymphoblastic Leukemia
1,393 Views
AnnualMeeting-SITC2017 2 years
Microbiome As A Predictor for Immunotherapy
Microbiome As A Predictor for Immunotherapy
Category: Acute Lymphoblastic Leukemia
724 Views
AnnualMeeting-SITC2017 2 years
Docetaxel With or Without Plinabulin for Stage 3b or 4 Non-Small Cell Lung Cancer
Docetaxel With or Without Plinabulin for Stage 3b or 4 Non-Small Cell Lung Cancer
Category: Acute Lymphoblastic Leukemia
791 Views
AnnualMeeting-SITC2017 2 years